Symbols / CGTX
CGTX Chart
About
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 91.81M |
| Enterprise Value | 52.85M | Income | -27.99M | Sales | — |
| Book/sh | 0.41 | Cash/sh | 0.45 | Dividend Yield | — |
| Payout | 0.00% | Employees | 25 | IPO | — |
| P/E | — | Forward P/E | -3.10 | PEG | — |
| P/S | — | P/B | 2.51 | P/C | — |
| EV/EBITDA | -1.18 | EV/Sales | — | Quick Ratio | 6.20 |
| Current Ratio | 6.45 | Debt/Eq | 1.04 | LT Debt/Eq | — |
| EPS (ttm) | -0.47 | EPS next Y | -0.34 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 15:00 | ROA | -78.99% |
| ROE | -109.73% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 88.27M |
| Shs Float | 81.45M | Short Float | 8.84% | Short Ratio | 7.28 |
| Short Interest | — | 52W High | 3.83 | 52W Low | 0.22 |
| Beta | 1.25 | Avg Volume | 923.06K | Volume | 550.87K |
| Target Price | $3.50 | Recom | None | Prev Close | $1.04 |
| Price | $1.04 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.50
Mean price target
2. Current target
$1.04
Latest analyst target
3. DCF / Fair value
$-6.18
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.04
Low
$3.00
High
$4.00
Mean
$3.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-04 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-11-21 | reit | B. Riley Securities | Buy → Buy | $3 |
| 2025-11-19 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-08-08 | main | Chardan Capital | Buy → Buy | $4 |
| 2025-06-26 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-05-27 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-05-08 | main | Chardan Capital | Buy → Buy | $4 |
| 2025-03-24 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-21 | main | Chardan Capital | Buy → Buy | $8 |
| 2025-02-26 | main | Chardan Capital | Buy → Buy | $11 |
| 2024-12-19 | up | B. Riley Securities | Neutral → Buy | $2 |
| 2024-12-19 | main | Chardan Capital | Buy → Buy | $11 |
| 2024-12-19 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-11-27 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-15 | main | Chardan Capital | Buy → Buy | $11 |
| 2024-11-04 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-10-31 | main | Chardan Capital | Buy → Buy | $11 |
| 2024-08-12 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-08-06 | down | B. Riley Securities | Buy → Neutral | $1 |
| 2024-08-01 | main | HC Wainwright & Co. | Buy → Buy | $7 |
- Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely? - Yahoo Finance Fri, 05 Dec 2025 08
- Cognition Therapeutics (NASDAQ: CGTX) maps Phase 3 AD trial after 95% decline slowdown - Stock Titan Mon, 01 Dec 2025 08
- B. Riley Securities Reiterates Cognition Therapeutics (CGTX) Buy Recommendation - Nasdaq Fri, 21 Nov 2025 08
- Cognition Therapeutics: A High-Stakes Bet On A Single Drug - Why I Hold (NASDAQ:CGTX) - Seeking Alpha Fri, 21 Nov 2025 08
- New Analyst Forecast: $CGTX Given $3.0 Price Target | CGTX Stock News - Quiver Quantitative Wed, 19 Nov 2025 08
- CGTX (CGTX) CFO reports tax-withholding share disposition on RSU vesting - Stock Titan Wed, 18 Feb 2026 21
- Cognition Therapeutics (CGTX) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance Wed, 08 Oct 2025 07
- Lewy body dementia patients get more time on zervimesine treatment - Stock Titan hu, 05 Feb 2026 08
- $CGTX stock is up 42% today. Here's what we see in our data. - Nasdaq hu, 10 Jul 2025 07
- Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress - Yahoo Finance Fri, 11 Jul 2025 07
- Cognition (NASDAQ: CGTX) completes Phase 2 enrollment at 540; 15% on Leqembi or Kisunla - Stock Titan hu, 13 Nov 2025 08
- CGTX, RVPH, SHOT, SONN, AKTX Rally After-Hours On Clinical Updates And Fed Rate Cut Momentum - Nasdaq hu, 18 Sep 2025 07
- Cognition Therapeutics (NASDAQ: CGTX) sets FDA Type C meeting on Phase 3 DLB - Stock Titan Wed, 03 Dec 2025 08
- $30M Stock Offering: Cognition Therapeutics Advances Phase 3 Programs for Neurodegenerative Drug - Stock Titan Wed, 27 Aug 2025 07
- Breakthrough Alzheimer's Drug Zervimesine Advances to Phase 3 with Novel Blood Test Strategy - Stock Titan ue, 12 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 800000 | — | — | Stock Award(Grant) at price 0.00 per share. | RICCIARDI LISA | Chief Executive Officer | — | 2026-02-03 00:00:00 | D |
| 1 | 200000 | — | — | Stock Award(Grant) at price 0.00 per share. | DOYLE JOHN BRENDAN | Chief Financial Officer | — | 2026-02-03 00:00:00 | D |
| 2 | 400000 | — | — | Stock Award(Grant) at price 0.00 per share. | CAGGIANO ANTHONY | Officer | — | 2026-02-03 00:00:00 | D |
| 3 | 75000 | — | — | Stock Award(Grant) at price 0.00 per share. | RICCIARDI LISA | Chief Executive Officer | — | 2025-12-18 00:00:00 | D |
| 4 | 30000 | — | — | Stock Award(Grant) at price 0.00 per share. | DOYLE JOHN BRENDAN | Chief Financial Officer | — | 2025-12-18 00:00:00 | D |
| 5 | 65000 | — | — | Stock Award(Grant) at price 0.00 per share. | CAGGIANO ANTHONY | Officer | — | 2025-12-18 00:00:00 | D |
| 6 | 7729 | 6492 | — | Conversion of Exercise of derivative security at price 0.84 per share. | FLETCHER AARON G.L. | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-19 00:00:00 | D |
| 7 | 75000 | — | — | Stock Award(Grant) at price 0.00 per share. | RICCIARDI LISA | Chief Executive Officer | — | 2025-07-29 00:00:00 | D |
| 8 | 30000 | — | — | Stock Award(Grant) at price 0.00 per share. | DOYLE JOHN BRENDAN | Chief Financial Officer | — | 2025-07-29 00:00:00 | D |
| 9 | 65000 | — | — | Stock Award(Grant) at price 0.00 per share. | CAGGIANO ANTHONY | Officer | — | 2025-07-29 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -33.48M | -25.51M | -21.13M | -13.38M |
| TotalUnusualItems | -195.00K | 0.00 | 0.00 | 2.65M |
| TotalUnusualItemsExcludingGoodwill | -195.00K | 0.00 | 0.00 | 2.65M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -33.97M | -25.79M | -21.40M | -11.72M |
| ReconciledDepreciation | 266.00K | 252.00K | 235.00K | 93.00K |
| EBITDA | -33.68M | -25.51M | -21.13M | -10.73M |
| EBIT | -33.95M | -25.76M | -21.37M | -10.82M |
| NetInterestIncome | -25.00K | -27.00K | -28.00K | -893.00K |
| InterestExpense | 25.00K | 27.00K | 28.00K | 893.00K |
| NormalizedIncome | -33.78M | -25.79M | -21.40M | -14.37M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -33.97M | -25.79M | -21.40M | -11.72M |
| TotalExpenses | 34.42M | 25.92M | 21.33M | 11.15M |
| TotalOperatingIncomeAsReported | -53.97M | -50.72M | -43.55M | -28.60M |
| DilutedAverageShares | 39.73M | 30.03M | 23.64M | 5.19M |
| BasicAverageShares | 39.73M | 30.03M | 23.64M | 5.19M |
| DilutedEPS | -0.86 | -0.86 | -0.91 | -3.13 |
| BasicEPS | -0.86 | -0.86 | -0.91 | -3.13 |
| DilutedNIAvailtoComStockholders | -33.97M | -25.79M | -21.40M | -16.25M |
| NetIncomeCommonStockholders | -33.97M | -25.79M | -21.40M | -16.25M |
| PreferredStockDividends | 4.53M | |||
| NetIncome | -33.97M | -25.79M | -21.40M | -11.72M |
| NetIncomeIncludingNoncontrollingInterests | -33.97M | -25.79M | -21.40M | -11.72M |
| NetIncomeContinuousOperations | -33.97M | -25.79M | -21.40M | -11.72M |
| PretaxIncome | -33.97M | -25.79M | -21.40M | -11.72M |
| OtherIncomeExpense | 471.00K | 158.00K | -35.00K | 328.00K |
| OtherNonOperatingIncomeExpenses | 666.00K | 158.00K | -35.00K | -2.32M |
| SpecialIncomeCharges | -195.00K | 0.00 | 0.00 | 443.00K |
| GainOnSaleOfBusiness | -195.00K | 0.00 | ||
| OtherSpecialCharges | -443.00K | |||
| GainOnSaleOfSecurity | 2.21M | |||
| NetNonOperatingInterestIncomeExpense | -25.00K | -27.00K | -28.00K | -893.00K |
| InterestExpenseNonOperating | 25.00K | 27.00K | 28.00K | 893.00K |
| OperatingIncome | -34.42M | -25.92M | -21.33M | -11.15M |
| OperatingExpense | 34.42M | 25.92M | 21.33M | 11.15M |
| OtherOperatingExpenses | -19.55M | -24.80M | -22.22M | -17.45M |
| ResearchAndDevelopment | 41.68M | 37.20M | 30.32M | 18.57M |
| SellingGeneralAndAdministration | 12.29M | 13.53M | 13.23M | 10.03M |
| GeneralAndAdministrativeExpense | 12.29M | 13.53M | 13.23M | 10.03M |
| OtherGandA | 12.29M | 13.53M | 13.23M | 10.03M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 59.85M | 32.17M | 28.99M | 22.23M |
| ShareIssued | 59.85M | 32.17M | 28.99M | 22.23M |
| TotalDebt | 814.00K | 1.24M | 1.48M | 0.00 |
| TangibleBookValue | 18.75M | 24.47M | 40.25M | 51.27M |
| InvestedCapital | 19.03M | 25.02M | 40.88M | 51.27M |
| WorkingCapital | 18.41M | 24.05M | 39.85M | 51.13M |
| NetTangibleAssets | 18.75M | 24.47M | 40.25M | 51.27M |
| CapitalLeaseObligations | 535.00K | 694.00K | 844.00K | 0.00 |
| CommonStockEquity | 18.75M | 24.47M | 40.25M | 51.27M |
| TotalCapitalization | 18.75M | 24.47M | 40.25M | 51.27M |
| TotalEquityGrossMinorityInterest | 18.75M | 24.47M | 40.25M | 51.27M |
| StockholdersEquity | 18.75M | 24.47M | 40.25M | 51.27M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -195.00K | -199.00K | -198.00K |
| OtherEquityAdjustments | -195.00K | -199.00K | -198.00K | |
| RetainedEarnings | -175.16M | -141.19M | -115.40M | -94.00M |
| AdditionalPaidInCapital | 193.85M | 165.83M | 155.82M | 145.45M |
| CapitalStock | 60.00K | 32.00K | 29.00K | 22.00K |
| CommonStock | 60.00K | 32.00K | 29.00K | 22.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 11.48M | 10.69M | 10.18M | 7.86M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 342.00K | 520.00K | 2.38M | 0.00 |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| DerivativeProductLiabilities | 0.00 | |||
| NonCurrentAccruedExpenses | 0.00 | |||
| NonCurrentDeferredLiabilities | 0.00 | 1.69M | 0.00 | |
| NonCurrentDeferredRevenue | 0.00 | 1.69M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 342.00K | 520.00K | 695.00K | 0.00 |
| LongTermCapitalLeaseObligation | 342.00K | 520.00K | 695.00K | 0.00 |
| CurrentLiabilities | 11.14M | 10.17M | 7.79M | 7.86M |
| OtherCurrentLiabilities | 1.19M | |||
| CurrentDeferredLiabilities | 1.07M | 1.70M | 1.70M | 753.00K |
| CurrentDeferredRevenue | 1.07M | 1.70M | 1.70M | 753.00K |
| CurrentDebtAndCapitalLeaseObligation | 472.00K | 718.00K | 783.00K | |
| CurrentCapitalLeaseObligation | 193.00K | 174.00K | 149.00K | 0.00 |
| CurrentDebt | 279.00K | 544.00K | 634.00K | |
| OtherCurrentBorrowings | 279.00K | 544.00K | 634.00K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.53M | 1.17M | 870.00K | 1.28M |
| PayablesAndAccruedExpenses | 8.08M | 6.58M | 4.44M | 4.63M |
| CurrentAccruedExpenses | 6.09M | 2.89M | 1.22M | 466.00K |
| Payables | 1.98M | 3.69M | 3.22M | 4.17M |
| AccountsPayable | 1.98M | 3.69M | 3.22M | 4.17M |
| TotalAssets | 30.23M | 35.16M | 50.42M | 59.14M |
| TotalNonCurrentAssets | 679.00K | 941.00K | 2.78M | 145.00K |
| OtherNonCurrentAssets | 1.73M | |||
| NetPPE | 679.00K | 941.00K | 1.05M | 145.00K |
| AccumulatedDepreciation | -1.16M | -1.05M | -953.00K | -870.00K |
| GrossPPE | 1.83M | 1.99M | 2.00M | 1.01M |
| OtherProperties | 1.20M | 1.19M | 1.06M | 1.01M |
| MachineryFurnitureEquipment | 140.00K | 140.00K | 129.00K | 1.00K |
| BuildingsAndImprovements | 498.00K | 657.00K | 813.00K | 0.00 |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 29.55M | 34.22M | 47.65M | 58.99M |
| OtherCurrentAssets | 1.86M | 3.02M | 2.41M | 2.00M |
| PrepaidAssets | 1.99M | |||
| Receivables | 2.69M | 1.28M | 3.67M | 2.27M |
| OtherReceivables | 2.69M | 1.28M | 3.67M | 2.27M |
| CashCashEquivalentsAndShortTermInvestments | 25.01M | 29.92M | 41.56M | 54.72M |
| CashAndCashEquivalents | 25.01M | 29.92M | 41.56M | 54.72M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -28.48M | -16.16M | -18.70M | -3.66M |
| RepaymentOfDebt | -739.00K | -811.00K | -1.40M | -268.00K |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 24.35M | 5.33M | 5.32M | 44.22M |
| CapitalExpenditure | -4.00K | -147.00K | -171.00K | -27.00K |
| EndCashPosition | 25.01M | 29.92M | 41.56M | 54.72M |
| BeginningCashPosition | 29.92M | 41.56M | 54.72M | 5.19M |
| EffectOfExchangeRateChanges | 0.00 | 4.00K | -1.00K | -11.00K |
| ChangesInCash | -4.91M | -11.64M | -13.16M | 49.54M |
| FinancingCashFlow | 23.57M | 4.52M | 5.55M | 53.20M |
| CashFlowFromContinuingFinancingActivities | 23.57M | 4.52M | 5.55M | 53.20M |
| NetOtherFinancingCharges | -128.00K | 8.94M | ||
| ProceedsFromStockOptionExercised | 82.00K | 0.00 | 1.62M | 310.00K |
| NetCommonStockIssuance | 24.35M | 5.33M | 5.32M | 44.22M |
| CommonStockIssuance | 24.35M | 5.33M | 5.32M | 44.22M |
| NetIssuancePaymentsOfDebt | -739.00K | -811.00K | -1.40M | -268.00K |
| NetLongTermDebtIssuance | -739.00K | -811.00K | -1.40M | -268.00K |
| LongTermDebtPayments | -739.00K | -811.00K | -1.40M | -268.00K |
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -4.00K | -147.00K | -171.00K | -27.00K |
| CashFlowFromContinuingInvestingActivities | -4.00K | -147.00K | -171.00K | -27.00K |
| NetPPEPurchaseAndSale | -4.00K | -147.00K | -171.00K | -27.00K |
| PurchaseOfPPE | -4.00K | -147.00K | -171.00K | -27.00K |
| OperatingCashFlow | -28.47M | -16.02M | -18.53M | -3.63M |
| CashFlowFromContinuingOperatingActivities | -28.47M | -16.02M | -18.53M | -3.63M |
| ChangeInWorkingCapital | 1.29M | 4.85M | -943.00K | 2.84M |
| ChangeInOtherWorkingCapital | -635.00K | -1.69M | 2.63M | 501.00K |
| ChangeInOtherCurrentLiabilities | -159.00K | -150.00K | -121.00K | 0.00 |
| ChangeInOtherCurrentAssets | -1.73M | 0.00 | ||
| ChangeInPayablesAndAccruedExpense | 1.85M | 2.44M | -749.00K | 3.43M |
| ChangeInAccruedExpense | 343.00K | 1.27M | ||
| ChangeInPayable | -1.09M | 2.17M | ||
| ChangeInAccountPayable | -1.09M | 2.17M | ||
| ChangeInPrepaidAssets | 1.63M | 1.85M | -1.30M | 21.00K |
| ChangeInReceivables | -1.41M | 2.39M | -1.41M | -1.11M |
| OtherNonCashItems | 318.00K | 383.00K | ||
| StockBasedCompensation | 3.75M | 4.35M | 3.57M | 5.18M |
| DepreciationAmortizationDepletion | 266.00K | 252.00K | 235.00K | 93.00K |
| DepreciationAndAmortization | 266.00K | 252.00K | 235.00K | 93.00K |
| Depreciation | 266.00K | 252.00K | 235.00K | 93.00K |
| OperatingGainsLosses | 195.00K | -416.00K | ||
| GainLossOnInvestmentSecurities | 27.00K | |||
| NetForeignCurrencyExchangeGainLoss | 195.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -33.97M | -25.79M | -21.40M | -11.72M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CGTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|